Short answer
LB PHARMACEUTICALS INC (LBRX) filed an 8-K current report with the SEC on August 11, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 results for quarter ended June 30, 2026.
LB PHARMACEUTICALS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026
- Press release furnished as Exhibit 99.1 contains the financial results
- Earnings disclosure gives investors access to the company’s latest quarterly performance and financial condition
Item EX-99.1 · Exhibit EX-99.1
- Q2 net loss $51.6M, versus $4.9M; R&D reached $44.1M as Phase 3 NOVA-2 spending accelerated
- NOVA-2 schizophrenia topline data pulled forward to first half 2027, with planned FDA pre-NDA meeting in second half 2027
- Cash, equivalents and marketable securities $327.8M at June 30, plus $150.0M private placement proceeds
- Management expects funding beyond Q2 2029, supporting schizophrenia readout and planned bipolar depression and MDD milestones
- Pipeline expansion targets negative schizophrenia symptoms and Alzheimer’s psychosis/agitation, increasing potential but broadening execution demands
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other LB PHARMACEUTICALS INC 8-K filings
Get the next LBRX 8-K as it lands
Follow LBRX for push alerts, or ask the research agent what this filing means.